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ABSTRACT 
STUDY OBJECTIVES - Insomnia in cancer patients is prevalent, persistent and confers risk 
for physical and psychological disorder. We must better understand how insomnia develops 
in cancer patients and explore the main contributors to its chronicity so that insomnia 
management protocols can be integrated more effectively within cancer care. This study 
monitors the etiology of insomnia in breast cancer patients and identifies risk factors for its 
persistence. 
METHODS – 173 females with newly diagnosed, non-metastatic breast cancer were tracked 
from diagnosis for 12-months. Participants completed monthly sleep assessments using the 
Insomnia Severity Index (ISI) and 3-monthly health-related quality-of-life assessments using 
the European Organisation for Research and Treatment of Cancer - Breast (EORTC QLQ-
C30-BR23) scale. Clinical data on disease status and treatment regimens were also assessed.  
RESULTS – Prior to diagnosis, 25% of participants reported sleep disturbance, including 8% 
with insomnia syndrome (IS). Prevalence increased at cancer diagnosis to 46% (18% IS) and 
remained stable thereafter at around 50% (21% IS). We also explored sleep status transitions. 
The most common pattern was to remain a good sleeper (34%-49%) or to persist with 
insomnia (23%-46%).  77% of good sleepers developed insomnia during the 12-month period 
and 54% went into insomnia remission. Chemotherapy (odds ratio=0·08, 95% ci 0·02-0·29, 
p<·001) and pre-diagnosis ISI scores (odds ratio=1·13/unit increase in pre-diagnosis sleep 
score, 95% ci 1·05-1·21, p=·001) were identified as the main risk factors for persistent 
insomnia. 
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CONCLUSIONS – These data advance our understanding of insomnia etiology in cancer 
patients and help identify those who should be prioritised for insomnia management 
protocols. 
KEYWORDS – Insomnia, Cognitive Behavioral Therapy, Epidemiology, Mental Health 
 
STATEMENT OF SIGNIFICANCE –  
 
This study explores the longitudinal course of insomnia in women with a diagnosis of breast 
cancer.  Results demonstrate that insomnia is a persistent condition following breast cancer 
diagnosis that results in significant adverse outcomes, particularly in those patients receiving 
chemotherapy. Effective insomnia treatment programmes such as Cognitive Behavior 
Therapy for insomnia (CBT-I) should be initiated at the earliest possible opportunity 
following cancer diagnosis in order to reduce the prevalence and impact of sleep disturbance 
during cancer treatment. In addition, patients with a history of sleep disturbance and/or those 
scheduled to receive chemotherapy should be closely monitored throughout the cancer 
treatment and rehabilitation phases and if required, offered more intensive forms of CBT-I 
following completion of active cancer treatment.  
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INTRODUCTION 
Breast cancer survival has doubled in the last forty years and UK net five year survival is 
87%.  Improving life quality amongst breast cancer survivors has thus become increasingly 
important. Insomnia is the most commonly reported mental health complaint in the UK 
1
 and 
as such, is a significant public health concern.
 
Around 25% of adults report poor sleep, with 
an estimated 8-10% meeting diagnostic criteria for insomnia syndrome.
2
 These rates are 
considerably higher amongst those with chronic health conditions. Data from cancer 
populations report that 25-69% have difficulty sleeping, with 18-29% reporting insomnia 
disorder.
3–5
 The highest prevalence rate is found in breast cancer patients, where 
approximately half of all those diagnosed report poor sleep. A previous study of three 
hundred breast cancer survivors reported that 51% experienced insomnia symptoms and 19% 
met diagnostic criteria for insomnia disorder.
6
 However, despite increasing awareness of the 
pervasiveness of insomnia within cancer groups, scientific reports of insomnia prevalence 
remain variable and wide-ranging.
7
 This is partly due to studies utilizing different insomnia 
definitions, measurements and timing of assessments.
5 
A previous report by Savard (2011) on the natural history of insomnia in cancer patients 
(mixed sites)  reported data on incidence
a
, persistence
b
,  remission
c
 and relapse
d
 over the  
eighteen month period following diagnosis.
8
 [
a
change of status from good sleep (at one time 
point) to insomnia symptoms or syndrome (at the next time point), 
b
presence of insomnia 
(symptoms or syndrome) at two consecutive time points, 
c
change in status from insomnia 
(symptoms or syndrome) to good sleep at the subsequent time point, 
d
resurgence of insomnia 
following remission]. The study revealed high rates of insomnia at baseline (59%), including 
28% with insomnia syndrome. Insomnia became less prevalent over the eighteen-month 
assessment period but remained pervasive at the end of the study (36%). Approximately 15% 
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of patients experienced a first incidence of insomnia during the study and around 20% 
experienced relapse. Patients with insomnia syndrome were much less likely to experience 
remission than those with insomnia symptoms and those with insomnia syndrome at baseline 
retained that sleep status throughout the study.  
Using operational diagnostic criteria to distinguish between insomnia syndrome and 
symptoms is an important differentiation, particularly in prospective studies. However, 
previous work in this area has included diverse cancer sites, which has led to significant 
differences between participant characteristics and characteristics of those who declined to 
participate. Similarly, due to the diversity of cancer treatment regimens across mixed cancer 
sites, cross-comparison between groups is difficult. Therefore, the exploration of insomnia 
evolution in a large cohort of breast cancer patients, encompassing active and follow-up 
treatment phases, permits a useful assessment of the progression from normal sleep to acute, 
then (potentially) persistent insomnia within a single, homogeneous group. Exploring the 
evolution of insomnia within breast cancer also helps to inform sleep management protocols, 
specifically with regard to when and how they would be most useful for patients. Therefore, 
study aims are (i) describe the natural history of insomnia in breast cancer patients by 
measuring rates of insomnia incidence, persistence, remission and relapse and (ii) identify 
potential demographic, clinical and psychological factors that contribute to persistent 
insomnia after cancer treatment. 
 
PATIENTS AND METHODS 
Participants and Recruitment 
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173 female breast cancer patients participated. Inclusion criteria included confirmed 
diagnosis of non-metastatic breast cancer, diagnosis < three months and prognosis > six 
months. Exclusion criteria were (i) untreated/unstable psychiatric illness, diagnosis of another 
sleep disorder and male gender. We excluded male breast cancer patients because they are 
few in number and as such, are likely to have different psychological characteristics. To 
avoid selection bias and priming effects, participants were advised that they were 
contributing to a study monitoring general wellbeing and health-related symptoms. 
Recruitment took place across multiple hospital sites in west central Scotland. Clinical teams 
identified eligible patients and the project researcher met with them at a scheduled clinic visit 
to provide further information and complete consent, eligibility and screening procedures. 
Recruitment was not restricted to individuals who met criteria for insomnia. Rather, we 
enrolled a cohort, some of whom would develop clinical insomnia or experience exacerbation 
of pre-existing clinical insomnia since diagnosis (Insomnia Syndrome), some of whom would 
display symptoms of insomnia without fulfilling all diagnostic criteria of insomnia syndrome 
(Insomnia Symptoms), and some of whom would continue to sleep well (Good Sleepers). 
Study Design 
We adopted a prospective quantitative approach in which females with newly diagnosed 
breast cancer were tracked during their cancer care. The planned study sample size 
calculation was based on the scenario of detecting a 20% difference in incidence of persistent 
insomnia post treatment (30% v 50%) between two categories of a predictive variable (e.g. 
XRT yes/no) with 75% of patients falling into the category with the smaller persistent 
insomnia rate.
9
 This required 250 patients (80% power, 5% level of statistical significance).  
In practice, the persistent insomnia rate was lower (15%) and only 173 patients were 
recruited within the study period.  On this basis, the study provides approximately 85% 
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power to detect a difference from 5%-25% in persistent insomnia rates between groups as 
outlined above.  If the split of patients between categories of a prognostic variable is closer to 
50:50 than 25:75, the power to detect associations of this magnitude will be greater than 85% 
(equivalently, associations of a smaller magnitude can be detected with the same power).  For 
variables such as age (examined as continuous variables), the power should also be greater 
than 85%.   
Measures and Procedure 
Prior to enrollment, interested patients were assessed for eligibility using the Glasgow Sleep 
Centre Screening Interview (GSCSI). This comprises assessments of sleep history, screening 
for other sleep disorders and a full history of physical and psychological health. Those who 
met inclusion criteria were enrolled and completed monthly sleep status assessments.  These 
monthly assessments were completed from month 0 (baseline) to month 12 using the 
Insomnia Severity Index (ISI). The ISI is a seven item measure, validated for cancer patients, 
which is considered a core assessment tool for insomnia research studies.
10
 Based on criteria 
outlined in Savard (2011), data from the ISI was combined with data on sleep medication use 
and duration of sleep problem, to classify patients into one of three sleep status groups at 
each assessment point; Insomnia Syndrome (IS), Insomnia Symptoms (ISym) or Good 
Sleepers (GS). These groups were defined as follows: IS group – patient meets criteria for 
insomnia, presents symptoms of initial, maintenance or late insomnia at least 3 nights per 
week for minimum of 1 month, is dissatisfied with sleep, reports psychological distress or 
daytime impairment related to sleep difficulties. If prescribed medication is used as a sleep-
promoting agent at least 3 nights per week, patients are automatically classified as IS 
regardless of the above; ISym group – patient presents symptoms of initial, maintenance or 
late insomnia at least 3 nights per week without fulfilling all criteria of IS (i.e. may be 
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satisfied with sleep, not report distress or daytime consequences, or sleep difficulties could 
last for < 1 month) or, will be dissatisfied with sleep quality but without symptoms of initial, 
maintenance or late insomnia. If prescribed medication is used as a sleep promoting agent 
less than three nights per week or over-the-counter medication at least one night per week 
participants are automatically classified as ISym regardless of the above; GS group – patients 
is satisfied with sleep, does not report symptoms of initial, maintenance or late insomnia, 
does not use prescribed or over-the-counter medication as a sleep-promoting agent. 
Alongside monthly sleep assessments, patients also completed an additional, retrospective ISI 
at month 0. Given the potential impact of diagnosis upon sleep, the purpose of this 
retrospective account was to establish sleep status 3 months prior to this event. However, due 
to the potential unreliability of retrospective accounts, we assessed the validity of these pre-
diagnosis ISI scores.  Patients completed a second retrospective ISI at month 12, which we 
then correlated with the actual month 9 ISI assessment. The correlation between the 
retrospective and the actual ISI was 0·91 with 94% scores being within five points of each 
other. This suggests that these retrospective accounts were reliable. 
Patients also completed the European Organisation for Research and Treatment of Cancer - 
Breast (EORTC QLQ-C30-BR23) scale. This is a cancer-specific measure of health-related 
quality of life comprising three symptom scales (fatigue, pain, and nausea and vomiting).  
This measure also includes a breast cancer specific module that assesses body image, sexual 
functioning, future perspective, systemic therapy side effects and breast symptoms. Patients 
completed this measure every three months from month 0 to month 12. Once all assessments 
were completed, individuals who continued to have difficulty sleeping had the option of 
receiving CBT. Patients had the option of completing these assessment online or via postal 
return. 52% of the sample opted for postal return. 
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Statistical Analyses 
In order to describe the natural history of insomnia in breast cancer patients, descriptive 
tabulations, associated histograms and bar charts are primarily used.  To examine insomnia 
persistence and remission duration, Kaplan-Meier techniques were employed. To identify 
factors that predict susceptibility to developing persistent insomnia over a twelve month 
period, we examined the relationship between patient, tumor and treatment characteristics 
and the proportion of patients who developed persistent insomnia syndrome (PIS) during the 
post cancer-treatment phase. PIS is defined as a sleep status of IS present on 3 separate 
occasions, during the post treatment follow-up phase (T8 – T12). The post treatment follow-
up phase was defined as months 8-12 in this study, as all patients had completed 
chemotherapy by month 7. Patients who completed less than 3 ISI assessments during this 
period were excluded from the analysis (n=3). We also examined the influence of worst 
recorded symptom scores (from month 0-6 EORTC QLQ-C30/BR23 data) on the 
development of PIS.  
The association of each variable with the development of PIS was examined in a univariate 
fashion based on Pearson’s chi-square test (exact version) for categorical variables or the 
Mann-Whitney U-test for continuous variables.  Those variables with a significant 
association at the 25% level were entered in a stepwise fashion into a multivariable logistic 
regression model to determine a set of variables that were significantly associated with the 
development of PIS.  Variables were retained if they were statistically significant at the 5% 
level.  The final logistic regression model was assessed for goodness of fit using the Hosmer-
Lemeshow test. In table 1, Pearson’s chi-square test (exact version) was used to determine the 
association with first major assessment point completed. All analyses were done using SPSS 
v22.0 (Chicago, IL). 
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RESULTS 
Of the 393 patients approached, 42 were excluded and 178 declined to participate, resulting 
in a participation rate of 49% (n = 173) (refer to Figure I for full exclusion/refusal details).  
As previously stated, patients were eligible to enroll on the study if their diagnosis was within 
the previous three month period. For clarity, these patients are presented separately as 
‘recruited at month 0’ or ‘recruited at month 3’, depending on which assessment point was 
closest to their date of written consent.  As outlined in Figure 1, 80 (46%) patients were 
enrolled at month 0 (diagnosis) and 93 (54%) were enrolled at month 3.  
 
Insert Figure 1 
The mean age of the sample was 58 years. Most patients were married (53·2%) and either 
retired (35·8%) or on sick leave from work (36·4%). The majority of patients had a stage I 
(38·2%) or stage II (26·0%) disease, consistent with study inclusion criteria. 67·6% of the 
sample had breast-conserving surgery. The remaining 26·6% had a mastectomy, 37·0% of 
whom also had breast reconstruction.  In terms of anti-cancer therapy, 46·2% of patients 
received chemotherapy, 93·6% received radiotherapy and 84·4% received adjuvant hormonal 
therapy. There were minimal differences between patients recruited at month 3 and those 
recruited at month 0.  The only statistically significant difference was in T-stage where month 
0 patients tended to have smaller tumours (T1 58·8% vs 39·8%, p=·028).  This difference 
was partially reflected in the overall stage of disease where month 0 patients tended to have 
earlier disease (stage I 47·5% v 30·1%, p=·059). Both the pre-diagnosis [Mean=4·4, S.D=5·7 
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(patients recruited at month 0); M=3·9, S.D=5·7 (patients recruited at month 3)] and month 3 
[M=9·0, S.D=6·9 (patients recruited at month 0); M=8·9, S.D=6·6 (patients recruited at 
month 3)] ISI scores were very similar at the two recruitment time-points.  Full details on 
patient demographics are presented in Table 1 
 
Insert Table 1 
Prevalence of Insomnia over Time 
Prior to cancer diagnosis, 75·1% [se=3·2%] of patients were good sleepers (GS), 16·8% 
[2·8%] reported symptoms of insomnia (ISym) and 8·1% [2·0%] reported insomnia 
syndrome (IS), using recognized ISI criteria. Therefore, the point prevalence of insomnia 
(combining those with IS and ISym) at pre-diagnosis was 24·9% [3·3%]. This rate increased 
at diagnosis (month 0) to 46·1% [5·6%], with rates remaining stable at around 50% thereafter 
(46·1% - 56·3%). When looking at prevalence of IS separately over this same period, 8·1% 
of patients reported IS at pre-diagnosis. This figure rises to 17·9% [4·3%] at diagnosis and 
remains at around 21% (18·2% - 24%) until month 11. At month 11, rates of IS dropped to 
14·9% before increasing again to 18·5% at month 12. At pre-diagnosis, 16·8% of patients 
report ISym, which rises to 28·2% [5·1%] at diagnosis and remains at approximately 30% 
thereafter (28·1% - 3·9%). Figure II shows rates of insomnia (both IS and ISym) double at 
diagnosis and remain relatively steady across the following 12-month period with half of the 
total sample reporting chronic, unremitting insomnia. 
 
Insert Figure 2 
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Sleep Status Transitions  
The analysis of insomnia incidence, remissions and relapse data over the 12-month period, is 
based on the cohort recruited at month 0 who had no more than one missing assessment (68 
patients; 85·1% of month 0 cohort).  In terms of incidence, 64·7% (n=44) of these patients 
reported being GS at pre-diagnosis. However, 77·3% [6·3%] of these had a first incidence of 
insomnia (where ISI score >7) at some point during the 12-month study period. In terms of 
remission, 55·9% of the total cohort (n=38) developed insomnia at some point over the 
assessment period (including the pre-diagnosis assessment) and of these patients, 44·8% 
[8·1%] experienced a subsequent insomnia remission. The persistence and remission 
durations of insomnia were estimated using data on all patients without a missing assessment 
(n=132). Of these, 106 developed insomnia at some point and insomnia persisted for a 
median of four months (95% confidence interval 2-6 months). 71 (54%) patients experienced 
insomnia remission at some point during the study and remission persisted for some time, 
providing there was no immediate relapse at the next assessment.  The median remission 
duration was nine months (95% confidence interval 2-9 months). 
At every time interval, with the exception of pre-diagnosis to month 0, the most common 
sleep status transitions are either to persist with insomnia or to remain a good sleeper. As 
illustrated in Figure 3, rates for remaining a good sleeper range from 34·2% [5·4%] to 49·0% 
[4·0%]. Rates for insomnia persistence range from 23·1% [4·8%] to 46·1% [3·9%] (from 
40% [5·7%] to 46·1% excluding the pre-diagnosis to month 0 transition). Insomnia incidence 
rates range from 4·5% [1·7%] to 23·1% [4·8%] (from 4·8% [1·7%] to 13·2% [3·9%] 
excluding the pre-diagnosis to month 0 transition) and rates for insomnia remission range 
from 3·8% [1·5%] to 11·2% [2·6%]. Overall, the most probable current sleep status 
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corresponds to retaining the previous sleep status in every instance except one (pre-diagnosis 
to diagnosis transition).  
  
Insert Figure 3 
 
Common Sleep Trajectories 
This analysis is based on the cohort of patients who were recruited at month 0 who had no 
more than one missing assessment (68 patients; 85·1% of cohort). To reduce the number of 
possible sleep trajectories, the categories ‘IS and ‘ISym’ were merged. There were six 
distinct trajectories that accounted for 43% of the patients; 12 patients (17·6%) with the 
trajectory ‘good sleeper’ throughout, 6 patients (8·8%) with the trajectory ‘insomnia’ 
throughout, 5 patients (7·4%) who were good sleepers at pre-diagnosis and then had insomnia 
for the subsequent twelve months.  There are three trajectories, which have 2 patients each (1 
with 11 months ‘good sleeper’ and ‘insomnia’ once at month 5; 2 with insomnia throughout 
apart from 1 month). The remaining thirty nine trajectories are distinct to single patients. 
Insert Table 2 
 
Risk Factors for Developing Persistent Insomnia Syndrome Post Cancer Treatment 
As described above, patients with PIS during the post cancer treatment phase are defined as 
having a sleep status of IS present on three separate occasions, during the post treatment 
follow-up phase. Specifically, in our analysis, insomnia syndrome was identified by 
examining ISI scores over months 8-12 of the study, excluding those patients with less than 
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three scores (n=3). One-hundred and fifty patients had all 5 ISI scores assessed over months 
8-12, 12 were missing 1 ISI score and 8 were missing 2 ISI scores.  Of these 20 patients with 
one or two missing scores the presence/absence of persistent insomnia was ambiguous in 5 
(IS present on at least one assessment), but for the purposes of the analysis this small 
percentage of the total patient number has been assumed not to have persistent insomnia.   Of 
the 170 patients included in the analysis, 26 (15%) met criteria for persistent insomnia 
syndrome post cancer treatment.  The association of persistent insomnia with individual 
patient demographic, disease and treatment details is presented in table 2.   A multiple 
logistic regression analysis examining demographic, clinical and treatment factors shows that 
the key parameters associated with insomnia syndrome after cancer treatment are pre-
diagnosis sleep score and whether the patient receives chemotherapy. Patients who had no 
chemotherapy were much less likely to develop insomnia syndrome (3·3%, 3/91) compared 
to those receiving chemotherapy (29·1%, 23/79) (odds ratio=0·08, 95% ci 0·02-0·29, 
p<·001). A higher pre-diagnosis sleep score was associated with a higher chance of 
developing insomnia syndrome (odds ratio=1·13/unit increase in pre-diagnosis sleep score, 
95% ci 1·05-1·21, p=·001).  The chance of developing persistent insomnia in those with a 
pre-diagnosis ISI score > 8 was 32·4% (11/34) compared to 11·0% (15/136) for those with 
lowers scores. In the 16 patients who received chemotherapy and had a pre-diagnosis ISI 
score >8, the persistent insomnia rate was 62·5%.  When data on patients’ worst symptoms 
over the first six months were entered into the regression, the worst recorded systemic 
therapy side effect and arm symptom scores completely replaced chemotherapy and pre-
diagnosis sleep score in the model. Patients who had a high systemic therapy side effect score 
had a much higher chance of developing insomnia syndrome (odds ratio=1·04/unit increase 
in worst systemic therapy side effect score, 95% ci 1·01-1·07, p=·010), as did patients with 
high arm symptom scores (odds ratio=1·05/unit increase in worst arm symptom score, 95% ci 
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1·02-1·08, p<·001).  Of the 47 patients who had worst arm symptom scores >33, 19 (40·4%) 
developed persistent insomnia compared to 4/103 (3·9%) with lower scores.  Similarly, of the 
76 patients who had worst systemic therapy side effect scores >33, 22 (28·9%) developed 
persistent insomnia compared to 1/74 (1·4%) with lower scores.  In the 37 patients who had 
both these symptom scores >33, the persistent insomnia rate was 51·4% (19/37). 
 
DISCUSSION 
Breast cancer patients frequently report disturbed sleep during diagnosis/treatment, and 
persistently after discharge from anti-cancer therapy. However, the evolution of insomnia 
over time is not well established in this population. Therefore, this study explored the 
naturally occurring trajectory of insomnia, in a sample of newly diagnosed breast cancer 
patients, over a 12-month period. Monthly data on insomnia incidence, persistence, remission 
and relapse were examined and factors that contributed to these pathways were identified.  
The point prevalence of insomnia at pre-diagnosis was 25%, comprising 8% with IS and 17% 
with ISym. This prevalence increased at diagnosis to 46% (18% IS and 28% ISym) and 
remained relatively stable thereafter at around 50% (21% IS and 30% ISym). This elevated 
prevalence of IS throughout the 12-month study period is considerably greater than the 
prevalence reported by the general population (8%-10%).
11,12
 Also, the stability of insomnia 
over time challenges Savard’s (2011) findings, where prevalence significantly decreased 
throughout the cancer trajectory. 77% of those who were good sleepers prior to cancer 
developed insomnia at some point during the 12-month assessment period. In addition, most 
patients who met criteria for IS retained that status throughout the 12-month period, which is 
contrary to findings reported in population based samples.
13,14
 Our data suggest that cancer is 
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a precipitating factor for insomnia and once insomnia develops, it remains persistent over 
time. 
In terms of predicting those most at risk of developing persistent insomnia syndrome, 
analyses identified two main factors; chemotherapy and pre-diagnosis ISI score. Patients who 
received chemotherapy were much more likely to develop persistent insomnia syndrome 
post-cancer treatment, than those who did not receive chemotherapy. This is an important 
finding because, to the best of our knowledge, no longitudinal studies have demonstrated the 
predictive value of chemotherapy on insomnia syndrome after the completion of active 
cancer treatment. Studies that have explored the relationship between chemotherapy and 
sleep have demonstrated that chemotherapy is associated with increased insomnia symptoms 
during the delivery of chemotherapy treatment and report a deleterious effect of 
chemotherapy on insomnia symptoms over time.
15-19
 Similarly, and unsurprisingly, poorer 
pre-diagnosis sleep was associated with a greater chance of developing persistent insomnia 
syndrome post-cancer treatment. However, when treatment side-effects and breast-specific 
symptoms were explored, these superseded chemotherapy and pre-diagnosis ISI score as best 
predictors of persistent insomnia syndrome, post-cancer treatment. Patients who had high 
systemic therapy side-effect scores and high arm symptom scores, had a much higher chance 
of developing IS than those who did not.  
These data are helpful in identifying patients most likely to experience sleep disturbance, 
whilst minimizing confounding factors related to mixed cancer sites and diverse treatment 
regimens. However, although focusing on the evolution of insomnia in breast cancer 
specifically permits clearer within-groups comparisons, variation does still exist in terms of 
disease characteristics, treatment regimens and follow-up/after-care support. This diversity 
may explain why symptom management strategies within oncology services are often 
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piecemeal and unsystematic. It may also explain the well documented absence of effective 
sleep management programs for cancer patients, despite the considerable evidence supporting 
cognitive behavioral therapy (CBT) as a first-line treatment for insomnia associated with 
cancer.
20–23
 This absence may be explained by a lack of appreciation for the extent to which 
episodes of insomnia will persist or remit over time. Therefore, the importance of assessing 
insomnia evolution in cancer patients is clear. Insomnia is a well-known risk factor for 
impaired function and for development of other medical and mental disorders, resulting in 
increased health care utilization.
24
 Given the increasing number of breast cancer survivors 
(currently 22% of all cancer survivors) who are likely to have comorbid symptoms (including 
insomnia), there is considerable burden on healthcare providers to implement symptom 
management strategies to cope with these increasing demands. Data that facilitate the 
improved understanding of insomnia evolution over time will undoubtedly lead to more 
tailored and accessible insomnia treatment. 
Strengths of this study include the recruitment of a clinical sample of breast cancer patients 
directly from oncology clinics, utilizing very few exclusion criteria. This emphasizes the 
generalizability of study outcomes. We conducted monthly sleep assessments, providing a 
very clear picture of sleep status variability during active cancer treatment and post-treatment 
rehabilitation phases. Despite this rigorous data collection protocol, retention rate was very 
high throughout the study. However, several limitations exist in the study. First, we recruited 
only females with breast cancer. Therefore it is unclear whether our findings would extend to 
patients with other cancer types. A second limitation of the study is the absence of a 
diagnostic interview/questionnaire for assessing insomnia. Sleep status categories were 
determined by ISI data and sleep medication use. However, we acknowledge that utilising 
DSM-V criteria to make this assessment would have enhanced the validity of the study. The 
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relatively high refusal rate also limits the external validity of the study. This is mainly due to 
the number of eligible patients (n = 178) who declined to participate. Reasons given for non-
participation varied, with the largest number (n=69) giving no reason. Most commonly, 
patients said they felt too unwell (n=41) had too much going on (n=34) or didn’t want to 
commit to a 1-year assessment protocol (n=27). Therefore it is possible that our sample 
represents those patients who are comparably high-functioning.  
This work is of significant clinical importance. In our experience, cancer patients with sleep 
difficulties value those difficulties being appropriately addressed. Evidence suggests that 
improving sleep enhances engagement with cancer treatment and contributes to a reduction in 
co-morbid mental health complaints.
25
 Currently, the psychological care of cancer patients 
during cancer treatment and rehabilitation fails to include appropriate sleep management 
strategies. This study emphasizes the importance of reconsidering the priority given to sleep 
within cancer care.  
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Figure Captions 
Figure 1 – Participant demographic, disease and treatment details 
Figure 2 - Prevalence of Insomnia by Assessment Time-Point 
Figure 3 - Sleep Status Transitions 
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Table 1 – Patient demographic, disease and treatment details 
 First major assessment point completed (month of entry) 
0 (n=80) 3 (n=93) Total (n=173) 
Column N % Count Column N % Count Column N % Count 
Employment Status at recruitment 
(p=.558) 
Employed 18.8% 15 20.4% 19 19.7% 34 
Unemployed 3.8% 3 7.5% 7 5.8% 10 
Sick leave 33.8% 27 38.7% 36 36.4% 63 
Retired 40.0% 32 32.3% 30 35.8% 62 
Missing 3.8% 3 1.1% 1 2.3% 4 
Marital status 
(p=.752) 
Married 46.3% 37 59.1% 55 53.2% 92 
Single 12.5% 10 14.0% 13 13.3% 23 
Divorced 13.8% 11 8.6% 8 11.0% 19 
Widowed 13.8% 11 10.8% 10 12.1% 21 
Living with partner 5.0% 4 4.3% 4 4.6% 8 
Separated 2.5% 2 2.2% 2 2.3% 4 
Missing 6.3% 5 1.1% 1 3.5% 6 
Menopausal Status 
(p=.293) 
Pre-menopause 23.8% 19 22.6% 21 23.1% 40 
Peri-menopause 3.8% 3 9.7% 9 6.9% 12 
Post-menopause 53.8% 43 47.3% 44 50.3% 87 
Missing 18.8% 15 20.4% 19 19.7% 34 
Ductal carcinoma in situ 
(p=1.00) 
No 90.0% 72 89.2% 83 89.6% 155 
Yes 10.0% 8 10.8% 10 10.4% 18 
Neoadjuvant treatment 
(p=.081) 
No 83.8% 67 93.5% 87 89.0% 154 
Yes 15.0% 12 6.5% 6 10.4% 18 
Overall stage of disease 
(p=.059) 
I 47.5% 38 30.1% 28 38.2% 66 
II 20.0% 16 31.2% 29 26.0% 45 
III 20.0% 16 18.3% 17 19.1% 33 
IV 2.5% 2 9.7% 9 6.4% 11 
DCIS 10.0% 8 10.8% 10 10.4% 18 
T-stage 
(p=.028) 
T1 58.8% 47 39.8% 37 48.6% 84 
T2 27.5% 22 44.1% 41 36.4% 63 
T3 1.3% 1 5.4% 5 3.5% 6 
T4 1.3% 1 .0% 0 .6% 1 
DCIS 10.0% 8 10.8% 10 10.4% 18 
Missing 1.3% 1 .0% 0 .6% 1 
Nodes staging 
(p=.808) 
N0 68.8% 55 63.4% 59 65.9% 114 
N1 5.0% 4 7.5% 7 6.4% 11 
N2 .0% 0 1.1% 1 .6% 1 
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N3 1.3% 1 2.2% 2 1.7% 3 
Missing 25.0% 20 25.8% 24 25.4% 44 
Metastatic staging 
(p=.498) 
M0 95.0% 76 88.2% 82 91.3% 158 
M1 .0% 0 2.2% 2 1.2% 2 
Missing 5.0% 4 9.7% 9 7.5% 13 
Oestrogen receptors 
(p=1.000) 
Negative 10.0% 8 8.6% 8 9.2% 16 
Positive 86.3% 69 79.6% 74 82.7% 143 
Missing 3.8% 3 11.8% 11 8.1% 14 
Progesterone receptors 
(p=.372) 
Negative 22.5% 18 26.9% 25 24.9% 43 
Positive 73.8% 59 60.2% 56 66.5% 115 
Missing 3.8% 3 12.9% 12 8.7% 15 
HER receptors 
(p=.612) 
Negative 88.8% 71 78.5% 73 83.2% 144 
Positive 8.8% 7 10.8% 10 9.8% 17 
Missing 2.5% 2 10.8% 10 6.9% 12 
Surgery type 
(p=.327) 
Wide Local Excision 8.8% 7 3.2% 3 5.8% 10 
Mastectomy 25.0% 20 28.0% 26 26.6% 46 
Quadrantectomy .0% 0 .0% 0 .0% 0 
No surgery .0% 0 .0% 0 .0% 0 
Lumpectomy 62.5% 50 61.3% 57 61.8% 107 
Other 3.8% 3 7.5% 7 5.8% 10 
Reconstructive surgery 
(p=.320) 
No 92.5% 74 87.1% 81 89.6% 155 
Yes 7.5% 6 12.9% 12 10.4% 18 
Chemotherapy  
Treatment (p=.284)  
No 58.8% 47 49.5% 46 53.8% 93 
Yes 41.3% 33 50.5% 47 46.2% 80 
Radiotherapy treatment 
(p=.228) 
No 3.8% 3 8.6% 8 6.4% 11 
Yes 96.3% 77 91.4% 85 93.6% 162 
Hormonal treatment (p=153) No 7.5% 6 15.1% 14 11.6% 20 
Yes 88.8% 71 80.6% 75 84.4% 146 
Missing 3.8% 3 4.3% 4 4.0% 7 
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Table 2 – Association of patient demographic, disease and treatment details with the presence of 
persistent insomnia syndrome post cancer treatment 
 
Insomnia syndrome? P-
value No (N=144) Yes (N=26) 
Row N % Count Row N % Count 
First major assessment point completed 
(month of entry) 
0 85.7% 66 14.3% 11 .832 
3 83.9% 78 16.1% 15  
Marital status Married 86.8% 79 13.2% 12 .269 
Single 86.4% 19 13.6% 3  
Divorced 77.8% 14 22.2% 4  
Widowed 76.2% 16 23.8% 5  
Living with partner 87.5% 7 12.5% 1  
Separated 75.0% 3 25.0% 1  
Missing 100.0% 6 .0% 0  
Employment Status at recruitment Employed 94.1% 32 5.9% 2 <.001 
Unemployed 60.0% 6 40.0% 4  
Sick leave 72.1% 44 27.9% 17  
Retired 95.1% 58 4.9% 3  
Missing 100.0% 4 .0% 0  
Menopausal Status Pre-menopause 75.0% 30 25.0% 10 .036 
Peri-menopause 72.7% 8 27.3% 3  
Post-menopause 90.6% 77 9.4% 8  
Missing 85.3% 29 14.7% 5  
Ductal carcinoma in situ No 85.5% 130 14.5% 22 .485 
Yes 77.8% 14 22.2% 4  
Neoadjuvant treatment No 87.4% 132 12.6% 19 .009 
Yes 61.1% 11 38.9% 7  
Missing 100.0% 1 .0% 0  
Overall stage of disease I 93.7% 59 6.3% 4 .136 
II 82.2% 37 17.8% 8  
III 78.8% 26 21.2% 7  
IV 72.7% 8 27.3% 3  
DCIS 77.8% 14 22.2% 4  
T- stage T1 88.9% 72 11.1% 9 .215 
T2 82.5% 52 17.5% 11  
T3 83.3% 5 16.7% 1  
T4 100.0% 1 .0% 0  
DCIS 77.8% 14 22.2% 4  
Missing .0% 0 100.0% 1  
N-stage N0 91.9% 102 8.1% 9 .157 
N1 72.7% 8 27.3% 3  
N2 100.0% 1 .0% 0  
N3 66.7% 2 33.3% 1  
N4 .0% 0 .0% 0  
Missing 70.5% 31 29.5% 13  
Metastatic staging M0 86.5% 134 13.5% 21 .261 
M1 50.0% 1 50.0% 1 
Missing 69.2% 9 30.8% 4 
Oestrogen receptors Negative 81.3% 13 18.8% 3 1.000 
Positive 84.3% 118 15.7% 22  
Missing 92.9% 13 7.1% 1  
Progesterone receptors Negative 81.4% 35 18.6% 8 .629 
Positive 84.8% 95 15.2% 17  
Missing 93.3% 14 6.7% 1  
HER receptors Negative 83.0% 117 17.0% 24 .314 
Positive 94.1% 16 5.9% 1  
Missing 91.7% 11 8.3% 1  
Surgery type Wide Local Excision 90.0% 9 10.0% 1 .014 
(p=.00
1, 
Mastec
tomy v 
Rest) 
Mastectomy 69.6% 32 30.4% 14 
lumpectomy 90.4% 94 9.6% 10 
other 
90.0% 9 10.0% 1 
Reconstructive surgery No 85.5% 130 14.5% 22 .485 
Yes 77.8% 14 22.2% 4  
Chemotherapy treatment No 96.7% 88 3.3% 3 <.001 
Yes 70.9% 56 29.1% 23  
Radiotherapy treatment No 80.0% 8 20.0% 2 1.000 
Yes 85.0% 136 15.0% 24  
Hormonal treatment No 85.0% 17 15.0% 3 1.000 
Yes 83.9% 120 16.1% 23  
Missing 100.0% 7 .0% 0  
Age Mean (sd, N) 59 (9,144) 52 (9, 26) .003 
Prediagnosis ISI score Mean (sd, N) 3.38 (4.65, 144) 8.15 (8.60.  26) .006 
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EORTC* Fatigue score Mean (sd, N) 42.6 (27.7, 128) 76.3 (23.0, 23) <.001 
EORTC Nausea/Vomiting score Mean (sd, N) 14.1 (22.6, 128) 29.7 (20.1, 23) <.001 
EORTC Pain score Mean (sd, N) 27.3 (27.8, 128) 68.1 (27.0, 23) <.001 
EORTC Dysnoea score Mean (sd, N) 23.4 (28.2, 128) 49.3 (33.1, 23) <.001 
EORTC Insomnia score Mean (sd, N) 48.2 (31.5, 128) 88.4 (23.8, 23) <.001 
EORTC Appetite loss score Mean (sd, N) 24.7 (31.9, 128) 43.5 (34.0,23) .005 
EORTC Breast symptoms score Mean (sd, N) 29.3 (19.9, 127) 51.1 (24.3, 23) <.001 
EORTC Constipation score Mean (sd, N) 27.3 (31.1, 128) 53.6 (31.4, 23) <.001 
EORTC Body image score Mean (sd, N) 71.1 (28.4, 127) 38.8 (29.8, 23) <.001 
EORTC Diarrhoea score Mean (sd, N) 14.3  (23.9, 128) 34.8 (32.5, 23) .001 
EORTC Arm symptoms score  Mean (sd, N) 17.1  (18.8, 127) 54.6 (25.9, 23) <.001 
EORTC Systemic therapy  side effects  
score 
Mean (sd, N) 
31.2 (21.8, 127) 60.5 (18.9, 23) 
<.001 
EORTC Upset by hair loss score Mean (sd, N) 24.5 (35.2, 127) 62.3 (40.6, 23) <.001 
* All EORTC scores range from 0-100 with 0 being “best” and 100 being “worst”, except for Body image where the direction is 
reversed. 
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Figure 1 
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Figure 2 
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Figure 3 
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